PsiThera TL1A small molecule

PsiThera is developing an oral small-molecule modulator of Tumor Necrosis Factor-like Ligand 1A (TL1A) for the treatment of inflammatory and immune-mediated diseases, specifically targeting inflammatory bowel disease (IBD) and rheumatological conditions. TL1A is a cytokine that plays a pivotal role in driving mucosal inflammation and intestinal fibrosis. While current TL1A-targeted therapies are primarily monoclonal antibodies (biologics), PsiThera's "Antibody-in-a-Pill" approach aims to achieve antibody-like inhibition of the TL1A pathway through an oral small molecule, potentially offering improved patient convenience and access. The program is currently in the preclinical discovery stage.

Other names

TL1A modulatorTL-1A modulatorTL 1A modulatorTL1A inhibitorTL-1A inhibitorTL 1A inhibitor